Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: OTC vaginal contraceptives

This article was originally published in The Tan Sheet

Executive Summary

OTC vaginal contraceptives: FDA's administrative record reopened until March 3, 1997 "to allow for comment on matters considered at the Nov. 22 joint meeting of the Nonprescription Drugs, Reproductive Health Drugs, Anti-Infective Drugs and Antiviral Drugs Advisory Committees," the agency announces in the Dec. 19 Federal Register. The committees discussed issues relevant to FDA's regulation of OTC spermicides, including the kind and scope of efficacy studies needed for the products ("The Tan Sheet" Nov. 25, pp. 1-7)...
Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS086483

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel